You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tirelizumab

Showing 26 - 38 of 38
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,

Recruiting
  • HNSCC
  • +2 more
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))

Recruiting
  • Cholangiocarcinoma, Intrahepatic
  • Shanghai, China
    Lulu@Huashan.Org.Cn
Aug 16, 2022

Extranodal Natural Killer T Cell Lymphoma Trial in China (Tislelizumab combined with Liposomal mitoxantrone HCl, Maintenance of

Recruiting
  • Extranodal Natural Killer T Cell Lymphoma
  • Tislelizumab combined with Liposomal mitoxantrone hydrochloride
  • Maintenance of tislelizumab
  • Beijing, China
  • +5 more
Jul 15, 2022

Lung Cancer Trial in Tianjin (PD-1 inhibitor, PARP inhibitor)

Recruiting
  • Lung Cancer
  • PD-1 inhibitor
  • PARP inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 23, 2022

Cervical Cancer Trial in Hangzhou (Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin)

Recruiting
  • Cervical Cancer
  • Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jul 12, 2022

Esophageal Squamous Cell Carcinoma Trial in Chongqing (Tislelizumab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chongqing, Chongqing, China
    Army Medical Center of the People's Liberation Army
May 26, 2023

Nasopharyngeal Carcinoma Trial in Beijing (Tislelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Beijing, Beijing, China
    National Cancer Center /National Clinical Research Center for Ca
Jul 4, 2022

Hepatocellular Carcinoma Trial in Guangzhou (PD-1 mAb, Radiofequencey or microwave ablation)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1 monoclonal antibody
  • Radiofequencey or microwave ablation
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 4, 2022

Gray Zone Lymphoma, Relapse/Recurrence, Chemo Effect Trial (PD-1 inhibitor +ICE)

Not yet recruiting
  • Gray Zone Lymphoma
  • +2 more
  • PD-1 inhibitor +ICE
  • (no location specified)
Apr 25, 2021

Esophageal Cancer Trial in Tianjin (Arm A, Arm B)

Not yet recruiting
  • Esophageal Cancer
  • Arm A
  • Arm B
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Sep 24, 2023

Nasopharyngeal Carcinoma Trial in China (Tislelizumab, Placebo)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Zhanjiang, Guangdong, China
  • +3 more
Feb 17, 2022

Bladder Cancer Stage IV Trial in Guangzhou (Chidamide with tislelizumab)

Recruiting
  • Bladder Cancer Stage IV
  • Chidamide with tislelizumab
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Oct 8, 2020

Nasopharyngeal Carcinoma Trial in Guangzhou (GP combine with Tislelizumab neoadjuvant therapy+CCRT)

Recruiting
  • Nasopharyngeal Carcinoma
  • GP combine with Tislelizumab neoadjuvant therapy+CCRT
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 15, 2021